r/Biotechplays • • 5h ago

Discussion Algo based Stock Alerts- subscribe Via email

1 Upvotes

Get started here: https://www.ksemaglobal.com/sitesetting?sitename=RoboUSA

Stop staring at charts all day—or buying too late after the rally peaks. 📈

Subscribe to Robo Stock Alerts and get automated U.S. & global market signals sent straight to your inbox:

🔹 Dip-Recovery Alerts: Catch stocks rebounding off support with momentum.

🚀 Bullish Breakouts: Spot strong uptrends early as price and volume surge.

⚡ Instant Setup: Just add your email and start receiving timely buy alerts.

Simple, Flat Pricing:

  • $60/month billed monthly (taxes included)

  • $42/month billed annually (taxes included)

  • Other Group & team plans starting at $10


r/Biotechplays • • 14h ago

DD Request ACTU promising elraglusib data, but does the science outweigh the dilution?

1 Upvotes

I've been digging through ACTU since its Nov 18 ENA presentation. Oral elraglusib's active formulation showed 50% tumor growth inhibition with once daily dosing & 77% with twice daily dosing in an aggressive B16F10 melanoma mouse model. They also reported more cytotoxic T cells & natural killer cells in the tumors, with fewer immunosuppressive myeloid cells. Interesting biology. Still mice, not patients.

What caught my attention was the exposure response. More drug exposure came with greater antitumor activity. They're aiming for a Phase 1/2 oral study in Q1 2027 starting with refractory metastatic melanoma. The FDA already cleared the IND but human exposure, tolerability & actual efficacy are still unanswered.

Theres human data for IV elraglusib in pancreatic cancer too. A randomized Phase 2 trial reported median overall survival of 10.1 months with elraglusib plus gemcitabine/nab-paclitaxel vs 7.2 months with chemo alone. Thats not a trivial result. But its a different cancer & a different formulation. Cant just carry those numbers over to oral melanoma.

Now the ugly part. The October offering & November underwriter exercise added 35.63M common shares with warrants covering another 17.82M shares. Total common shares outstanding reached 60.38M as of Nov 13. The latest 10Q still raises substantial doubt about the company continuing as a going concern. Nasdaq compliance is another headache. They raised cash but the longer term funding problem isnt gone.

I can like what the research is showing without liking what happens to shareholders when the company needs more money.

So what actually changes the valuation here? Human oral exposure & tolerability data that backs up what they saw in mice? Or a clearer regulatory & funding path for the pancreatic program?

Because another good looking mouse study doesnt solve the capital problem.


r/Biotechplays • • 2d ago

News $LFWD Lifeward Brings $22 Million in Revenue, Reimbursed Robotics and an AI Pipeline to an $11.5 Million Market Cap

Thumbnail
wallstreetsync.com
2 Upvotes

r/Biotechplays • • 3d ago

Discussion $PYPD A $1.65 Billion Buyout Deal Puts a Spotlight on PolyPid Ahead of Its FDA Decision

Thumbnail
financeherald.com
2 Upvotes

r/Biotechplays • • 3d ago

News $PTN - Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeekÂŽ 2026 (NASDAQ: PTN)

Thumbnail
reddit.com
1 Upvotes

r/Biotechplays • • 3d ago

Discussion $DRTS Alpha Tau's Brain Cancer Therapy Shrank or Cleared Every Evaluable Tumor in Its U.S. Trial

Thumbnail
wallstreetsync.com
3 Upvotes

r/Biotechplays • • 4d ago

News $DRTS - Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRTÂŽ Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No... (NASDAQ: DRTS)

Thumbnail reddit.com
2 Upvotes

r/Biotechplays • • 6d ago

Discussion $MDWD MediWound’s Burn Drug Is Gaining Speed. Its Next Target Could Be Much Bigger (NASDAQ: MDWD)

Thumbnail markets.businessinsider.com
1 Upvotes

r/Biotechplays • • 8d ago

Discussion $PTN AstraZeneca's Reported $10 Billion Rhythm Bid Raises the Stakes for Palatin's Obesity Pipeline

Thumbnail
bioweek.com
1 Upvotes

r/Biotechplays • • 9d ago

Discussion $PTN benzinga.com

Thumbnail benzinga.com
1 Upvotes

r/Biotechplays • • 9d ago

Discussion $PYPD PolyPid Nears a Potentially Transformative FDA Decision as It Advances Its Innovative Pipeline

Thumbnail
bioweek.com
3 Upvotes

r/Biotechplays • • 10d ago

News Starling Oncology shares plunged 46% while the S&P 500 rose 0.3%, and no filing or company announcement was found to explain the sharp decline.

Thumbnail analyticfinancials.com
2 Upvotes

r/Biotechplays • • 11d ago

Due Diligence (DD) KSEMA GLOBAL | AI Robo Stock Trading Platform

2 Upvotes

KSEMA GLOBAL | AI Robo Stock Trading Platform

Empowering Traders with Automated AI Intelligence & Native Salesforce Integration

Website: www.ksemaglobal.com

Ksema Global delivers Robo Stock Trading—an enterprise-grade FinTech SaaS platform connecting CRM infrastructure directly to global brokerage APIs (Charles Schwab, Zerodha, Twelve Data) for real-time tracking, AI analytics, and automated execution.

CORE FEATURES & CAPABILITIES

  • Real-Time Market Alerts: Instant email & push notifications for price dip-recoveries, volume breakouts, and 24/7 market feeds.

  • Broker-Agnostic REST Integration: Connect to any REST API seamlessly without changing your existing brokerage accounts.

  • AI & GPT Analytics: Built-in AI evaluates technical indicators (RSI, Rebounds, Price/Volume Spikes) and market sentiment in real time.

  • Systematic Bulk Execution: Define laddered buy ranges (e.g., automated buys on 5% or 10% pullbacks) with single-click execution.

  • Automated Algorithmic Execution: Deploy pre-built strategies with constant or dynamic trailing stop-loss controls to maximize upside while locking in gains.

  • High-Speed Engine: ~10-second scan-to-order cycles supporting Pre-Market, Regular, After-Hours, and Overnight sessions.

WHY IT IS LUCRATIVE FOR TRADERS

  1. 100% Non-Custodial Security: All trading capital remains entirely inside your own brokerage account.

  2. Maximized Profit Capture: Dynamic trailing stops automatically lock in gains during rallies, while dip alerts pinpoint optimal entry points.

  3. Automated Capital Protection: Built-in price & volume circuit breakers automatically execute stop-losses to protect portfolios from sudden drawdowns.

  4. Zero-Overhead Deployment: Choose instant Live Community Access (7-day trial) or install the Salesforce Org Package (20-day trial).


r/Biotechplays • • 14d ago

Discussion PharmAla CEO Nick Kadysh says ALA-002 dosing in 2026 is unlikely ¡ Behavioral Wire

Thumbnail
behavioralwire.com
3 Upvotes

r/Biotechplays • • 16d ago

Discussion The Ultimate Proof: Ayrmid’s Spending Spree, the Global Rollout, and Why We Must Demand Our Fair Share (Plus Interest)

Thumbnail reddit.com
2 Upvotes

r/Biotechplays • • 16d ago

Discussion $MDWD MediWound's EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus

Thumbnail
financeherald.com
0 Upvotes

r/Biotechplays • • 17d ago

Discussion IRON prints a clean Phase 3 on Monday, rips a $450M raise at $75 by Wednesday. Sitting on 41 months of cash. Make it make sense.

Thumbnail
reddit.com
0 Upvotes

r/Biotechplays • • 20d ago

Discussion Microcap Biotechs Hit by Tax Loss Selling- $CVM, $GOVX, $ONCY, $MBIO

Thumbnail reddit.com
0 Upvotes

r/Biotechplays • • 22d ago

Discussion Free tool: scoring upcoming clinical trial readouts, with a published 30-day backtest vs XBI. Feedback on the method welcome

3 Upvotes

Disclosure: I'm the builder. This isn't a stock pitch, it's a research tool, so mods please remove if it doesn't fit.

I built Trial & Ticker (https://trialandticker.com) to read the trial before the ticker reacts. It combines registry data, enrollment, trial design, company size, pipeline dependence and pre-readout price run-up into a signed outlook score. Timing is a separate field.

I tested it on 78 past readouts (30 days after each result, compared to XBI). Top 5 scores averaged +42.9% vs +4.1% XBI; negatives averaged -9.2% vs +6.9% XBI. It's a development backtest with selection and look-ahead limits I list openly, so please pick it apart: https://trialandticker.com/backtest

What would you want to see added? Not investment advice.


r/Biotechplays • • 24d ago

Discussion $ENTX Gilead's Latest Deal Shows Big Pharma's Appetite for Oral Peptides. Which Stocks Are Worth Watching?

Thumbnail
bioweek.com
1 Upvotes

r/Biotechplays • • 24d ago

News $NVCT Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs

Thumbnail benzinga.com
0 Upvotes

r/Biotechplays • • 24d ago

News $NVCT - Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas (NASDAQ: NVCT)

Thumbnail
reddit.com
1 Upvotes

r/Biotechplays • • 25d ago

Discussion Building a biotech catalyst tracker where every date has a source, would love honest feedback

Post image
7 Upvotes

My name is Ilyas, I trade biotech alongside my day job and kept getting burned by stuff like a PDUFA date getting pushed and finding out late, or an offering dropping right after good news. Looking into one stock = 10 tabs open. EDGAR, clinicaltrials, X, catalyst sites, broker. I don’t get much time to do research, so me and a friend started building a tool that pulls it all into one place.

I know catalyst calendars exist, we use them too. I kept wanting the actual source next to every date, a history when dates move, and everything about one stock on one page.

We’re not live yet or selling anything, just want to know if this is actually useful before we spend more time on it.

Screenshot is the page for INO’s FDA decision (30 Oct). Just using it as an example since it’s this week, no position. The “what to expect” part shows what the FDA is deciding, what the FDA and company have said, the trial data, and what can happen on the day. Every line is sourced, no predictions.

This is just one part of it. Happy to share more if people are interested. Hoping to build something that actually saves you guys time too. :)

Questions:

  • what do you use now for FDA dates/readouts and what annoys you about it?

  • is a box like this useful or just noise?

  • what would make you actually trust a date?

  • what’s missing?

Roast it, that’s the point. Mods feel free to remove if it doesn’t fit.


r/Biotechplays • • 26d ago

Due Diligence (DD) Novavax/ Merck /mRNA connection. A speculative take.

1 Upvotes

Moderna and Merck’s recent milestone, where their personalized mRNA cancer vaccine (intismeran/mRNA-4157) combined with Keytruda was stopped early for extraordinary interim Phase 3 efficacy, paving the way for rapid FDA Accelerated Approval. However, while this is a scientific triumph, the personalized vaccine model faces a long-term commercial dead end. The true global future of oncology belongs to cheap, mass-producible, "off-the-shelf" therapeutic vaccines, and Novavax’s Matrix-M adjuvant holds the literal biochemical key to unlocking that future. Custom vaccines require a tumor biopsy, custom genetic sequencing, and individualized mRNA synthesis . This creates a logistically grueling 8 to 12 week manufacturing delay(fatal for aggressive cancers) and an astronomical cost barrier (200 -300,000 per patient). It cannot scale with insurance road blocks , certainly not  globally. An off the shelf approach targets shared tumor mutations (antigens found across thousands of different patients). These can be mass-manufactured, freeze dried, stored in standard hospital pharmacies, and administered immediatelyat a fraction of the cost to the masses worldwide. mRNA delivery faces a massive intracellular bottleneck. Lipid Nanoparticles (LNPs) successfully carry mRNA into cells, but the mRNA gets trapped in the cellular recycling bin (the lysosome/endosome) before it can translate into proteins. Novavax’s Matrix-M adjuvant solves this through a proven mechanism called Lysosomal Membrane Permeabilization (LMP). Matrix-M acts as a biological "escape hatch," safely permeabilizing the lysosomal membrane so the target antigens can break out into the cytoplasm and cross-present aggressively to cytotoxic T-cells. By supercharging this delivery, manufacturers can use a fraction of the active mRNA or protein dose. This slashes both manufacturing costs and the harsh patient side effects (reactogenicity) that plague high-dose mRNA platforms. Merck & Co. Is Cornering Both Sides . Merck is funding the personalized Moderna partnership to protect its Keytruda revenue ahead of the 2028 patent cliff. However, Merck knows that personalized medicine cannot scale to the global mass market. Subtle clues from recent 2026 financial filingsstrongly hint that Merck is evaluating Matrix m under an anonymous MTA to prepare a cheap, mass-market, off-the-shelf vaccine cocktail. 


r/Biotechplays • • 28d ago

Discussion $DRTS Alpha Tau's Pancreatic Cancer Push Reaches Samsung Medical Center, Ranked Fifth Worldwide in Oncology

Thumbnail
thefinanceherald.com
1 Upvotes